Literature DB >> 9822286

Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.

J L Teeling1, E R De Groot, A J Eerenberg, W K Bleeker, G Van Mierlo, L A Aarden, C E Hack.   

Abstract

IVIG preparations have biological effects in vivo that are not fully understood. Possible effects include the property to stimulate Fc receptors on various cell types. To study whether IVIG may interact with neutrophils we developed an in vitro system, in which neutrophils, in whole blood or purified, were incubated with IVIG and assessed for degranulation by measuring the release of elastase and lactoferrin in culture medium. All commercially available IVIG preparations tested induced degranulation of neutrophils when incubated for 2 h at therapeutically relevant concentrations. In studies with blocking antibodies against Fc receptors (FcR), this degranulation was shown to be dependent on Fc gammaRII, whereas Fc gammaRIII had no effect. Experiments with purified neutrophils as well as binding experiments with labelled IVIG preparations indicated that neutrophil degranulation resulted from a direct interaction of IVIG with neutrophils. Using gel filtration fractions, it was found that polymeric and dimeric IgG present in IVIG was mainly responsible for the degranulation. We suggest that degranulation of neutrophils may contribute to the (side)effects of IVIG treatment in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822286      PMCID: PMC1905117          DOI: 10.1046/j.1365-2249.1998.00697.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

2.  Transient neutropenia induced by intravenous immune globulin.

Authors:  E Ben-Chetrit; C Putterman
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

3.  Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation.

Authors:  D H Hechtman; M I Cybulsky; H J Fuchs; J B Baker; M A Gimbrone
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

4.  Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors.

Authors:  J Greenman; A L Tutt; A J George; K A Pulford; G T Stevenson; M J Glennie
Journal:  Mol Immunol       Date:  1991-11       Impact factor: 4.407

5.  Inhibition of neutrophil migration by tumor necrosis factor. Ex vivo and in vivo studies in comparison with in vitro effect.

Authors:  Y Otsuka; K Nagano; K Nagano; K Hori; J Oh-ishi; H Hayashi; N Watanabe; Y Niitsu
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

6.  Immunoglobulin G dimer: an idiotype-anti-idiotype complex.

Authors:  D L Tankersley; M S Preston; J S Finlayson
Journal:  Mol Immunol       Date:  1988-01       Impact factor: 4.407

7.  Neutropenia following intravenous immunoglobulin.

Authors:  P A Veys; M G Macey; C M Owens; A C Newland
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

8.  Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli.

Authors:  A A Creasey; P Stevens; J Kenney; A C Allison; K Warren; R Catlett; L Hinshaw; F B Taylor
Journal:  Circ Shock       Date:  1991-02

9.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

10.  Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis.

Authors:  J H Nuijens; J J Abbink; Y T Wachtfogel; R W Colman; A J Eerenberg; D Dors; A J Kamp; R J Strack van Schijndel; L G Thijs; C E Hack
Journal:  J Lab Clin Med       Date:  1992-02
View more
  8 in total

Review 1.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?

Authors:  P V Mohan; W Tarnow-Mordi; B Stenson; P Brocklehurst; K Haque; V Cavendish; A Cust
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

Review 2.  Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.

Authors:  Merry L Lindsey; Rugmani Padmanabhan Iyer; Mira Jung; Kristine Y DeLeon-Pennell; Yonggang Ma
Journal:  J Mol Cell Cardiol       Date:  2015-12-23       Impact factor: 5.000

3.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

4.  Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders.

Authors:  Alessandro Prezzo; Filomena M Cavaliere; Cinzia Milito; Caterina Bilotta; Metello Iacobini; Isabella Quinti
Journal:  Blood Transfus       Date:  2018-07-17       Impact factor: 3.443

5.  Different proteolytic mechanisms involved in Fc gamma RIIIb shedding from human neutrophils.

Authors:  P J Middelhoven; J D Van Buul; P L Hordijk; D Roos
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms.

Authors:  Sarah Casulli; Selma Topçu; Lakhdar Fattoum; Stephan von Gunten; Hans-Uwe Simon; Jean-Luc Teillaud; Jagadeesh Bayry; Srini V Kaveri; Carole Elbim
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

7.  Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation.

Authors:  Iwan Kustiawan; Ninotska I L Derksen; Theresa Guhr; Simone Kruithof; Wim Jiskoot; Gestur Vidarsson; Theo Rispens
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

8.  Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Authors:  Tania F Rowley; Shirley J Peters; Mike Aylott; Robert Griffin; Nicola L Davies; Louise J Healy; Rona M Cutler; Alison Eddleston; Thomas L Pither; Joshua M Sopp; Oliver Zaccheo; Gianluca Fossati; Katharine Cain; Andrew M Ventom; Hanna Hailu; Eleanor J Ward; John Sherington; Frank R Brennan; Farnaz Fallah-Arani; David P Humphreys
Journal:  Commun Biol       Date:  2018-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.